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Abstract
The malaria parasite Plasmodium falciparum invades human red blood cells via interactions 
between host and parasite surface proteins. By analyzing genome sequence data from human 
populations, including 1269 individuals from sub-Saharan Africa, we identify a diverse array of 
large copy number variants affecting the host invasion receptor genes GYPA and GYPB. We find 
that a nearby association with severe malaria is explained by a complex structural rearrangement 
involving the loss of GYPB and gain of two GYPB-A hybrid genes, which encode a serologically 
distinct blood group antigen known as Dantu. This variant reduces the risk of severe malaria by 
40% and has recently risen in frequency in parts of Kenya, yet it appears to be absent from west 
Africa. These findings link structural variation of red blood cell invasion receptors with natural 
resistance to severe malaria.
Malaria parasites cause human disease by invading and replicating inside red blood cells, 
which can lead to life-threatening complications that are a major cause of childhood 
mortality in Africa (1, 2). The invasion of red blood cells is orchestrated by the specific 
binding of parasite ligands to erythrocyte receptors (3), a stage at which genetic variation 
could influence the progression of infection. Indeed, a human genetic variant that prevents 
erythrocytic expression of the Duffy antigen receptor for chemokines (DARC), which is 
essential for invasion by Plasmodium vivax, is thought to have undergone a selective sweep 
resulting in the present-day absence of P. vivax malaria across most of sub-Saharan Africa 
(4). In contrast the main cause of malaria in Africa, P. falciparum, has an expanded family of 
erythrocyte binding ligands that target a different set of human receptors, most of which 
appear not to be required for invasion (5–7). Two such invasion receptors are the 
glycophorins GYPA and GYPB, which are abundantly expressed on the erythrocyte surface 
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and underlie the MNS blood group system (6, 8–10). The antigenic complexity of this 
system as well as rates of amino acid substitution and levels of diversity in African 
populations have led to speculation that this locus is under evolutionary selection due to 
malaria (8, 11–13).
In a recent genome-wide association study (GWAS), we identified alleles associated with 
protection from severe malaria on chromosome 4, between FREM3 and the cluster of genes 
encoding GYPE, GYPB and GYPA (14). Although the association signal did not extend to 
these genes and a functional variant was not identified, interpretation and further analysis of 
the association signal was inhibited by several factors. First, the GWAS samples were 
collected at multiple locations in sub-Saharan Africa, where levels of human genetic 
diversity are higher than in other parts of the world. This diversity remains underrepresented 
in genome variation reference panels. Second, the glycophorin genes are in a region of 
segmental duplication that is difficult to characterize due to high levels of paralogy. Notably, 
the region is known to harbor structural variation that contributes to the MNS blood group 
system but has not been characterized by next generation sequence data (15, 16). Here we 
aim to capture additional variation in sub-Saharan African populations, including structural 
variation, to determine the underlying architecture of the association signal in this region.
An African-enriched reference panel in the glycophorin region
We constructed a reference panel with improved representation of sub-Saharan African 
populations from countries where malaria is endemic. We performed genome sequencing of 
765 individuals from 10 ethnic groups in the Gambia, Burkina Faso, Cameroon and 
Tanzania, including 207 family trios (100 bp paired end (PE) reads, mean coverage 10x; 
Tables S1, S2). We focused on a region surrounding the observed association signal 
(chr4:140Mb-150Mb; GRCh37 coordinates). Genotypes at single nucleotide polymorphisms 
(SNPs) and short indels in the region were called and computationally phased (17–19) and 
combined with Phase 3 of the 1000 Genomes Project (20) to obtain a reference panel of 
3,269 individuals, including 1,269 Africans and a further 157 individuals with African 
ancestry (Fig. S1; Tables S1, S3). We imputed variants from this panel into the published 
severe malaria GWAS dataset comprising 4,579 cases of severe malaria and 5,310 
population controls from the Gambia, Kenya and Malawi and tested for association as 
described previously (14). The signal of association, formerly identified and replicated at 
SNPs lying between FREM3 and GYPE, extends over a region of at least 700 kb, and 
includes linked variants within GYPA and GYPB where association is only apparent with 
the additional African reference data (Fig. S2).
Identification of copy number variants
We next assessed copy number variation in the glycophorin region (defined here as the 
segmental duplication within which the three genes lie) for the sequenced reference panel 
individuals. The high level of sequence identity between the duplicate units presents a 
challenge for short read sequence analysis due to ambiguous mapping (Fig. 1A) (21). We 
therefore focused on changes in read depth at sites of high mappability and developed a 
hidden Markov model (HMM) to infer the underlying copy number state for each individual 
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in 1600 bp windows. We grouped individuals carrying similar copy number paths to define 
copy number variants (CNVs) and assign individual CNV genotypes.
Across the 3,269 samples, we identified eight deletions and eight duplications that were 
found in ≥2 unrelated individuals (referred to below as non-singleton CNVs), as well as at 
least 11 singleton variants (Figs. 1B, S3) (22). For reference, we label these variants by copy 
number type (DEL for deletion, DUP for duplication), and number them in order of 
frequency. To validate the CNV calls we analyzed transmission in family trios and observed 
segregation as expected with few exceptions (Table S4) (22). We also compared the CNV 
calls with the 1000 Genomes Project structural variant analysis (23), and found highly 
consistent copy number inference (98.8% of individuals have the same overall copy number 
call) but substantial improvements to individual genotypes in our analysis (Fig. S4) (22). 
Validation of the breakpoint of the most common variant (DEL1) by Sanger sequencing 
further confirmed the accuracy of our method (Figs. S5, S6 and Table S5) (22).
The variants ranged in length from 3.2 kb (the minimum possible with our method) to >200 
kb and included deletions and duplications of entire genes. Loss of GYPB was a common 
feature, with five different forms of GYPB deletion among the non-singleton CNVs (Fig. 
1B). Hybrid gene structures were another common feature, with two non-singleton CNVs 
predicted to generate GYPB-A or GYPE-A hybrids (Fig. S7). Some variants are predicted to 
correspond to known MNS blood group antigens while others have not previously been 
reported (Table S6) (22). Of the non-singleton CNVs, half (8/16) had a single pair of 
breakpoints in homologous parts of the segmental duplication, consistent with formation via 
non-allelic homologous recombination (NAHR; Fig. 1C). Of these, four share a breakpoint 
position, which coincides with a double-strand break (DSB) hotspot active in a PRDM9 C 
allele carrier (Figs. 1C, S8) (24).
CNVs in the glycophorin region were observed more frequently in Africa than other parts of 
the world (Fig. 2). In this dataset, the combined allele frequency of glycophorin CNVs in 
African populations was 11% compared to 1.1% in non-African populations, and most of the 
non-singleton CNVs (13/16) were identified in individuals of African ancestry. Among 
fourteen different ethnic groups sampled in Africa, the estimated frequency ranged from 
4.7-21% with the highest frequencies in west African populations.
Association with severe malaria
We sought to incorporate CNVs into the phased reference panel with the aim of imputing 
into our GWAS dataset. Computational phasing of CNVs is challenging, as published 
methods do not model CNV mutational mechanisms or non-diploid copy number at smaller 
variants within CNVs. To work around this, we excluded SNPs and short indels within the 
glycophorin region and relied on the trio structure of sequenced individuals to resolve 
haplotype phase between CNVs and flanking SNPs (18, 25). Haplotype clustering and cross-
validation predict good imputation performance for the three highest frequency CNVs, 
DEL1, DEL2, and DUP1 as well as for DUP4 (Figs. S9, S10, S11).
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We used this panel to impute CNVs into the severe malaria GWAS samples (Fig. S12) and 
tested for association as before. One of the imputed CNVs, DUP4, is associated with 
decreased risk of severe malaria (odds ratio, OR=0.60; 95% CI 0.50-0.72; Padditive = 
9.9x10-8; computed under an additive model of association using fixed-effect meta-analysis; 
Fig. 3A). Across populations, evidence for association at DUP4 is among the strongest of 
any variant in our data. Moreover, conditioning on the imputed genotypes at DUP4 in the 
statistical association model removes signal at all other strongly associated variants 
including the previously reported markers of association (e.g., conditional Padditive=0.32 at 
rs186873296; Figs. 3B, S13). DUP4 has an estimated heterozygous relative risk of 0.61 
(95% CI 0.50-0.75) and its genetic effect appears to be consistent with an additive model, 
although the low frequency of homozygotes makes it difficult to distinguish the extent of 
dominance (homozygous relative risk 0.31; 95% CI 0.09-1.06; n=24 homozygotes; Fig. 3C). 
Analysis of different clinical forms of severe malaria showed that DUP4 reduced the risk of 
both cerebral malaria and severe malarial anaemia to a similar degree (Table S7). We noted 
some evidence of additional associations in the region, including a possible protective effect 
of DEL2 (OR=0.63; 95%CI=0.42-0.94, Padditive=0.02), but no evidence of association with 
the more common DEL1, or with GYPB deletion status overall (P>0.1 using logistic 
regression). These results are compatible with a primary signal of association that is well 
explained by an additive effect of DUP4.
DUP4 is imputed with high confidence in both east African populations (Fig. 3D), where it 
is at substantially higher frequency than in the reference panel (Fig. S12). To independently 
confirm the imputed DUP4 genotypes, we analyzed SNP microarray data for intensity 
patterns indicative of copy number variation (Fig. 4) using a Bayesian clustering model 
informed by the sequenced DUP4 carriers (Fig. S14, Table S8) (22). Classification of GWAS 
samples was highly concordant with the imputed DUP4 genotypes in the east African 
populations (r2=0.96 in Kenya; r2=0.88 in Malawi; Table S9). Surprisingly, both imputation 
and the microarray intensity analysis suggest there may be no copies of DUP4 present 
among the 4791 Gambian individuals in the GWAS. This large frequency difference places 
DUP4 as an outlier compared with imputed variants at a similar frequency in the Gambia or 
in Kenya genome-wide (P=1.7x10-3 and P=5x10-3, respectively, based on the empirical 
distribution of frequencies; Fig. 5A). DUP4 also varies in frequency within east Africa (Fig. 
5B). Computation of haplotype homozygosity provides evidence that DUP4 is carried on an 
extended haplotype (P=0.012 for iHS (26, 27) based on the empirical distribution for 
variants of similar frequency genome-wide; Fig. 5C-D) that may have risen to its current 
frequency in Kenya relatively recently. We note that DUP4 is also absent from all but two of 
the reference panel populations (Fig. 2).
The physical structure of DUP4
The copy number profile of DUP4 is complex, with a total of six copy number changes that 
cannot have arisen by a single unequal crossover event from reference-like sequences (Figs. 
1B, 4B). At the gene level, this copy number profile corresponds to duplication of GYPE, 
deletion of the 3’ end of GYPB, duplication of the 5’ end of GYPB and triplication of the 3’ 
end of GYPA. To begin to understand the functional consequences of DUP4, we sought to 
reconstruct the physical arrangement of this variant by pooling data across the nine carriers 
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in the sequenced reference panel (eight Wasambaa individuals from Tanzania including three 
parent-child pairs, and a single African Caribbean individual from Barbados). First, analysis 
of coverage along a multiple sequence alignment of the segmental duplication corroborated 
the location of the six copy number changes from the HMM, with two pairs of breakpoints 
at homologous locations in the alignment (Fig. S15).
Next, we looked for sequenced read pairs spanning CNV breakpoints, which provide direct 
evidence of the structure of the underlying DNA. We identified read pairs that were mapped 
near breakpoints but with discordant positions (MQ>=1, absolute insert size > 1000 bp), 
including longer read data we generated for the 1000 Genomes individual who carries DUP4 
(HG02554; 300 bp PE reads on Illumina MiSeq to 13x coverage). Discordant read pairs 
supported the connection between each pair of homologous breakpoints as well as between 
the remaining two breakpoints, which lie in non-homologous sequence (Figs. 6A, S16). On 
the basis of the combined evidence from copy number changes, discordant read pairs, and 
homology between inferred breakpoints, we generated a model of the DUP4 chromosome 
that contains five glycophorin genes (Fig. 6B).
A prominent functional change on this structure is the presence of two GYPB-A hybrid 
genes, supported by several read pairs within intron 4 of GYPA and GYPB and the copy 
number profile. We confirmed the hybrid sequence by PCR-based Sanger sequencing of a 
4.1 kb segment spanning the breakpoint (Figs. 6B, S17, S18 and Table S10) (22). These data 
localize the breakpoint to a 184 bp section of GYPA and GYPB where the two genes have 
identical sequence (Fig. S19). If translated, the encoded protein would join the extracellular 
domain of GYPB to the transmembrane and intracellular domains of GYPA, creating a 
peptide sequence at their junction that is characteristic of the Dantu antigen in the MNS 
blood group system (28, 29). Moreover, like DUP4, the most common Dantu variant (termed 
NE type, here referred to as Dantu NE) is reported to have two such hybrid genes and lack a 
full GYPB gene (30). We sequenced genomic DNA from an individual serologically 
determined to be Dantu positive, and of NE type (150 bp PE reads on Illumina HiSeq to 18x 
coverage) and analyzed it using our HMM. The coverage profile and HMM-inferred copy 
number path, indistinguishable from those of DUP4 carriers, confirm identification of DUP4 
as the molecular basis of Dantu NE (Fig. 6C-D).
In addition to duplicate GYPB-A hybrid genes, these data reveal the full structure of this 
Dantu variant, including a duplicated copy of GYPE and the precise location of six 
breakpoints. Either complex mutational events or a series of at least four unequal crossover 
events are needed to account for the formation of this variant (confirmed by simulation; Fig. 
S20) (22). However, we find no potential intermediates and no obvious relationship between 
DUP4 and other structural variant haplotypes in the present dataset (Fig. S9) (22). Further 
analysis of discordant read pairs identifies a number of shorter discrepancies relative to the 
reference sequence that are consistent with gene conversion events (Fig. S21) and could be 
functionally relevant (e.g., Fig. S22).
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Discussion
Here we use whole-genome sequence data to identify at least 27 CNVs in the glycophorin 
region that segregate in global populations. In this study, 14% of sub-Saharan African 
individuals carry a variant that affects the genic copy number relative to the reference 
assembly. Our description of these variants complements the existing literature on antigenic 
variation associated with the MNS blood group system and offers additional insights. For 
example, the frequency of GYPB deletion is broadly commensurate with previous surveys of 
the S–s–U– blood group phenotype linked to absence of the GYPB protein, but the GYPB 
deletions in our data differ from the reported molecular variant (Fig. S23) (16, 22, 31–33).
Of the array of glycophorin CNVs identified, one (DUP4) is associated with resistance to 
severe malaria and explains the previously reported signal of association (14). While there 
may be other functional mutations on this haplotype, we propose that the direct 
consequences of this rearrangement are likely to drive the underlying causal mechanism for 
resistance to severe malaria. DUP4 was not present in the 1000 Genomes Phase 1 reference 
panel (used in (14)), and exists as a singleton in the 1000 Genomes Phase 3 reference panel. 
Thus, as previously observed at the sickle cell locus (34), mapping of the association signal 
by imputation was only possible with the inclusion of additional individuals in the reference 
panel.
Through additional sequencing, we have shown that DUP4 corresponds to the variant 
encoding the Dantu+ (NE type) blood group phenotype, thus linking the predicted hybrid 
genes to a serologically distinct hybrid protein that is expressed on the red blood cell (29, 
35). The few existing studies of Dantu+ (NE type) erythrocytes indicate high levels of the 
hybrid GYPB-A protein and lower levels of GYPA than wild type cells (35, 36). A single 
study reports parasite growth to be impaired in Dantu+ cells (37), making Dantu NE one of 
many glycophorin variants that have been hypothesized to influence malaria susceptibility or 
shown to have an effect in vitro (12, 37–40). Our results regarding a specific protective 
effect of DUP4, and the lack of evidence for other protective CNVs, suggest the relevance of 
these effects in natural populations may be complicated. We caution that many of the other 
CNVs are rare, such that larger sample sizes and direct typing may be required to test their 
effect in vivo.
These findings then raise the question of how DUP4 protects against malaria. GYPA and 
GYPB are exclusively expressed on the erythrocyte surface and are targeted by parasites 
during invasion (6, 7). P. falciparum EBA175 binds to the extracellular portion of GYPA 
(41), which is preserved in DUP4. P. falciparum EBL1 binds to the extracellular portion of 
GYPB (42) which is duplicated in DUP4 but joined to intracellular GYPA. The significance 
of the extra copy of GYPE or the absence of full GYPB in DUP4 is uncertain, since GYPE 
is not known to be expressed at the protein level (8, 43), and we do not observe evidence that 
absence of GYPB alone confers protection (Fig. 3A). GYPA and GYPB are known to form 
homodimers as well as heterodimers in the red cell membrane (33), so these copy number 
changes could have complex functional effects. There are physical interactions between 
GYPA and band 3 (encoded by SLC4A1) at the red cell surface (44) and parasite binding to 
GYPA appears to initiate a signal leading to increased membrane rigidity (45). Thus the 
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GYPB-A hybrid proteins seen in DUP4 could potentially affect both receptor-ligand 
interactions and the physical properties of the red cell membrane.
Previous surveys of the Dantu blood group antigen have indicated that it is rare (Table S11) 
(33, 46–48). We find that DUP4 is absent or at very low frequency outside parts of east 
Africa, with a frequency difference and extended haplotype consistent with a recent rise in 
frequency in Kenya. In contrast, the malaria-protective variant causing sickle-cell anaemia 
(rs334 in HBB), which is thought to be under balancing selection, has a similar frequency in 
both the Gambia and Kenya (Fig. 5A). One possibility for why DUP4 is not more 
widespread, given its strong protective effect against malaria, is that it has arisen recently 
without time for gene flow to facilitate its dispersion. Alternatively, this frequency 
distribution could be consistent with balancing selection, for example if it protects only 
against certain strains of P. falciparum that are specific to east Africa. The glycophorin 
region is near a signal of long-term balancing selection, and measures of polymorphism in 
both the human glycophorins and P. falciparum EBA175 have been suggestive of 
diversifying selection (11, 12, 49, 50). Although apparently not directly related to these 
signals, current selection on DUP4 may represent a snapshot of the long-term evolutionary 
processes acting at this locus. Mapping the allele frequency of DUP4 across additional 
populations could help clarify the nature of selection.
Recent GWAS have confirmed three other loci associated with severe malaria (HBB, ABO, 
ATP2B4), all of which are also related to red blood cell function (14, 51). However, only the 
association with GYPA and GYPB directly involves variation in invasion receptors. These 
receptors have been found to be non-essential in experimental models (7, 9), yet this result 
indicates important functional roles in natural populations. Intriguingly, there is marked 
variation among P. falciparum strains in preference for different invasion pathways in vitro 
(7); field studies that account for parasite heterogeneity and tests for genetic interactions 
may therefore be important in determining how DUP4 affects parasite invasion. The 
discovery that a specific alteration of these invasion receptors confers substantial protection 
provides a foundation for experimental studies on the precise functional mechanism, and 
may lead us towards novel parasite vulnerabilities that can be utilized in future interventions 
against this deadly disease.
Materials and methods
Sample collection and sequencing
Sequencing of African individuals—Blood samples from a total of 773 healthy 
individuals from 10 ethnic groups in four countries in sub-Saharan Africa were collected by 
MalariaGEN partners (www.malariagen.net) and the MRC Unit in the Gambia (http://
www.cggh.org/collaborations/mrc-unit-the-gambia) as part of ongoing projects (Fig. S1A 
and Tables S1, S2). Individuals were from the general population, with most collected in 
family trios except in Burkina Faso where individuals are unrelated. Genomic DNA was 
extracted and sequencing was performed on Illumina HiSeq 2000 at the Wellcome Trust 
Sanger Institute with 100 bp paired end reads to an average of 10x coverage. Reads were 
mapped to the GRCh37 human reference genome with additional sequences as modified by 
the 1000 Genomes Project (hs37d5.fa; (20)), using BWA (55) with base quality score 
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recalibration (BQSR) and local realignment around known indels as implemented in GATK 
(56, 57).
Sequence data curation—We used GATK HaplotypeCaller to compute an initial set of 
genotype likelihoods across samples at a genome-wide set of variants, including 
polymorphic sites from 1000 Genomes Phase 3 (58). We computed average coverage across 
the genome for each individual using BEDTools genomecov (59) and excluded seven Bantu 
individuals from Cameroon with less than 2x coverage across the genome, and one Wollof 
individual from the Gambia with less than 6x coverage and greater than 10% missing call 
rate in the GATK analysis. All further analyses described here are based on the 765 non-
excluded individuals.
We inferred the sex of sequenced samples based on the ratio of X chromosome coverage to 
autosomal coverage. To infer family relationships, we used lcMLkin (60) to compute 
maximum likelihood pairwise kinship estimates from the GATK-estimated genotype 
likelihoods at a thinned set of ~26,000 SNPs genome-wide. We then ran PRIMUS (61) to 
infer pedigrees from the kinship estimates and compared the inferred and reported 
relationships. Based on this we manually curated the family structure of sequenced samples 
by removing relationships incompatible with trio structure (IBD1 < 0.9 for parent-child 
relationship), swapping three individuals between trios with clear sample mixups, and 
exchanging parental labels in two trios to be consistent with the genetic sex of the parents. 
The curated dataset contains 207 trios, 16 duos, and 115 individuals without nominal close 
relationships. All trios and duos are unrelated to each other except for one extended family 
in the Wollof from the Gambia, which consists of a quad (two parents and two children, here 
encoded as two trios), where one of the children is a parent in an additional trio.
1000 Genomes sequence data—The 2,504 individuals from 26 populations in the 1000 
Genomes Phase 3 release (20) were analyzed. Bam files containing reads mapped to 
GRCh37 were downloaded from the 1000 Genomes FTP site (ftp://ftp.
1000genomes.ebi.ac.uk/vol1/ftp/data/; Fig. S1B and Table S3).
Overview of the glycophorin region
The glycophorin gene cluster on chromosome 4 results from segmental duplication events in 
the ancestor to African great apes (62) and is not related in sequence to GYPC on 
chromosome 2. By aligning segments of the reference sequence against one another, we 
identified the region of segmental duplication, here referred to as the glycophorin region, as 
chr4:144,706,830-145,069,066, and the three paralogous units of the segmental duplication 
as: GYPE unit, chr4:144,706,830-144,837,481; GYPB unit, chr4:144,837,482-144,947,716; 
GYPA unit, chr4:144,947,717-145,069,066. Each gene occupies ~30 kb toward the end of its 
~120 kb repeat unit. We generated a multiple sequence alignment of the reference sequence 
for the three units by running kalign (63) with default parameters, and calculated pairwise 
identity in 1600 bp windows along this alignment (Fig. 1A). The glycophorin genes are 
transcribed on the negative strand, and we adopt the convention of numbering exons and 
introns as they occur in the GYPA transcript (exon 3 is a pseudoexon in GYPB and exons 3 
and 4 are pseudoexons in GYPE). We focus on the three protein-coding genes, but note that 
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a long noncoding RNA is annotated between GYPE and GYPB (LOC101927636). The 
coordinates here, and throughout the paper, are given with respect to GRCh37.
Construction of a regional reference panel
Identification of polymorphic sites and genotype likelihood computation—To 
construct a regional reference panel we focused on the 10 Mb region chr4:140-150Mb, 
including a 500 kb margin at either end. We first assembled a list of previously identified 
SNPs and short indels from the 1000 Genomes Phase 3 (20), the Illumina Omni 2.5M array, 
the ExAC project (64) and the European Variation Archive (downloaded on 24th February 
2016; www.ebi.ac.uk/eva/), totaling 421,670 variants. We then used freebayes v1.0.2 (19) to 
calculate genotype likelihoods at these sites as well as at newly identified putatively 
polymorphic sites, across the 3,269 sequenced individuals. Freebayes was run in 10 kb 
chunks across the region. We filtered freebayes output to include all previously identified 
variants and high quality novel variants, i.e., novel variants with quality (QUAL) > 1, 
presence of supporting reads on both strands (SAF > 0 and SAR > 0) and both sides of the 
variant (RPL>1 and RPR>1), and high quality per alternate observation (QUAL/AO>10). In 
total, the filtered output contained 424,909 variants, of which 412,795 were among the 
previously identified variants.
Genotype calling and phasing—We next aimed to generate a high-quality set of 
genotype calls in the 765 individuals collected by MalariaGEN partners. We focused on sites 
with combined mean coverage between 7.5x and 13.5x, excluding approximately 4% and 
1% of variants with depth below or above this range respectively, and restricted to variants 
with allele count at least 2, leaving a total of 117,531 variants. We produced an initial set of 
genotype calls at these variants using BEAGLE 4.0 (beagle.r1399; (17)) without specifying 
family information. Based on the initial calls, we removed variants with more than five 
mendelian errors in the 207 trios, strong evidence for deviation from Hardy-Weinberg 
equilibrium (PHWE < 1x10-3 in the 542 individuals without parents in the dataset) or more 
than one alternate allele. We then re-ran BEAGLE on the remaining set of 111,167 variants, 
including family information, to produce genotype calls. We phased these genotypes using 
SHAPEIT2, specifying 400 selected and 200 random conditioning states, an effective 
population size of 17,469, and 10 burn-in, 8 pruning and 50 main iterations, and including 
trio information.
Finally, to form a joint reference panel across all individuals, we merged the phased 
haplotypes with the 1000 Genomes Phase 3 haplotypes (20) at the overlapping set of 
variants. The merged reference panel, which contains 96,676 variants in the region 
chr4:139.5-150.5Mb, is available for use in other studies (see https://www.malariagen.net/
resource/23).
Imputation and association testing at SNPs and short indels
Imputation and association testing—We used both the 1000 Genomes Phase 3 
reference panel (20) and the merged reference panel described above to impute genotypes 
into the previously published sets of severe malaria cases and population controls from the 
Gambia, Kenya and Malawi (14). In brief, we ran IMPUTE2 (65, 66) in 2 Mb chunks, using 
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Illumina Omni 2.5M genotype calls as previously described. A total of 5,621 (the Gambia), 
5,203 (Malawi), and 5,583 (Kenya) genotyped variants were included in the 11 Mb region 
considered. We specified 1,000 copying states (-k_hap 1000), an effective population size of 
20,000 (-Ne 20000) as recommended for African populations, and a buffer region of 500 kb. 
We removed reference panel individuals with parents in the panel before imputation.
We tested for association in each population under additive, dominant, recessive and 
heterozygote models using a logistic regression model as implemented in the program 
SNPTEST, including five principal components to account for population structure. We 
restricted analysis here to severe malaria cases with nonzero parasitaemia, as measured by 
blood slide at the time of admission, as this is likely to be the most accurate phenotype. For 
downstream meta-analysis, we omitted results for variants at low frequency (MAF < 0.5%) 
or with low imputation quality (IMPUTE info < 0.75) in each population.
We used fixed-effect meta-analysis to compute an estimate of the odds ratio across 
populations, along with a standard error and P-value, for each model. For additive model we 
refer to the resulting P-value as Padditive. Additionally, we computed a model-averaged 
Bayes factor (BFavg) reflecting the overall evidence for association as previously described 
(14). Meta-analysis results under the two imputation reference panels, as well as for the 
previously published 1000 Genomes Phase 1 reference panel imputation, are shown in Fig. 
S2.
Functional annotation of variants—We used Variant Effect Predictor (VEP; (67)) to 
annotate the functional consequences of all variants with evidence of association (BFavg>1). 
We noted one variant with VEP IMPACT rating ‘moderate’ with some evidence of 
association (rs147343123; nonsynonymous in exon 1 of GYPA, predicted deleterious; 
association test BFavg=17.34, Padditive=1.4x10-3 for 1000 Genomes imputation; 
BFavg=121.3, Padditive=1.5x10-4 for full panel imputation) (Fig. S2). We also noted that the 
nonsynonymous variant in FREM3 exon 1 previously found to have evidence of association 
(rs181620317; see (14)), is imputed at much lower frequency using both the 1000 Genomes 
Phase 3 panel and the full reference panel (e.g. frequency = 0.2% in Kenya using the full 
reference panel), and shows no evidence for association using genotype imputed from these 
panels.
Identification of copy number variation
Method to call copy number variation—To identify large CNVs across the 
glycophorin region, we implemented a hidden Markov model (HMM) to infer the 
underlying copy number state from the observed read counts. The input to the HMM is read 
depth, averaged over sites in windows of fixed length (here, 1600 bp) for each individual. To 
reduce the problems with mapping in the region, we included only (i) reads with at least a 
mapping quality (MQ) of 20; (ii) mappable sites, defined as sites with mappability >0.9, 
where mappability of a site is the mean value of the CRG mappability track for all 100-mers 
overlapping that site (21); (iii) windows with ≥25% of sites fulfilling this criterion; windows 
with fewer mappable sites were considered uninformative.
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We modeled the mean depth of coverage for individual i at window j, di,j, as normally 
distributed with mean and variance dependent on the assumed underlying copy number k 
(k=2 is the normal diploid state):
For copy number k=0 (homozygous deletion), we used a truncated normal distribution 
(truncated at 0) and assigned a variance of 0.04 to allow for spurious mapping. To account 
for systematic variation in coverage along the genome, we estimated a window-specific 
factor (wj) proportional to how much individuals with no copy number variation (k=2) are 
above or below their mean in that window. These define the emission probabilities for the 
HMM. We used a fixed transition matrix that assumes a low rate of switching with 
approximately 0.999 probability of remaining in the current copy number state; 1x10-4 for 
leaving the diploid state; 0.001 probability of returning to diploid (k=2) from a non-diploid 
state; and 1x10-5 probability of switching among non-diploid states.
We estimated μi, σi and wj by starting with an initial guess assuming everyone to be diploid 
across the region, and then running the Viterbi algorithm separately for each individual. We 
then recalculated μi and σi for each individual, only including windows in which the copy 
number is inferred to be 2, and wj for each window only including individuals in which the 
copy number is inferred to be 2. We iterated this algorithm until no further changes in the 
inferred underlying copy number paths were observed for any individuals.
CNV calling in the 3,269 sequenced individuals—We applied the HMM method 
described above to the full set of 3,269 individuals with sequence data in an 850 kb region 
including the glycophorin genes (chr4:144.35-145.20Mb). After inferring the copy number 
state paths for each individual, we then considered variants to be the same across individuals 
if the direction of copy number change was the same and both end points were within three 
bins of each other. Heterozygous triplications and homozygous duplications were 
differentiated by looking across individuals; variants that were always found in copy number 
state 4 were attributed as triplications. We excluded copy number variable segments that 
covered only a single bin or were outside the segmental duplication. We then considered 
copy number variable segments that were always found together to be a single CNV, and 
manually refined the few other copy number variable segments that were not found 
separately from other CNVs (22). This process identified 16 non-singleton variants and 28 
singleton variants (Figs. 1B, S3), although we note several caveats about the singleton CNVs 
including some that likely correspond to more common variants (22).
To validate the CNVs and genotype calls, we assessed inheritance in the MalariaGEN trios 
and compared genotype calls for the 1000 Genomes individuals with those released in the 
1000 Genomes Phase 3 paper on structural variants (Table S4, Fig. S4) (22, 23). We also 
designed PCR primers on either side of the DEL1 variant and generated Sanger sequence 
that confirmed and localized this breakpoint (Figs. S5, S6 and Table S5) (22).
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Phasing and imputation of CNVs
Initial phasing of CNVs—We investigated whether CNVs could be accurately phased 
relative to surrounding SNP variation in the regional reference. Collectively, non-singleton 
CNVs in our dataset cover a total of 350 kb (Fig. 1B), which extends over most of the region 
of segmental duplication surrounding the glycophorin genes. In principle, inference of CNV 
haplotype phase might benefit from copy-number-aware genotype calls at smaller variants 
within CNVs. However, implementing this is challenging as the state-of-the art phasing 
methods assume samples are diploid. A further possible issue is that read mapping, and 
hence the quality of SNP genotype calls, is likely to be impaired in such regions of 
segmental duplication.
Motivated by these observations, we took the following approach to phasing CNVs which 
leverages the family trio structure of sequenced individuals to infer accurate phase, using 
both SHAPEIT2 (18) and MVNCALL (25). First, we focused on the 765 sequenced 
individuals collected by MalariaGEN partners. We removed variants within the region of 
segmental duplication (here taken as chr4:144.7-145.07Mb) from the reference panel, and 
replaced these with CNV genotype calls, to form a single file with genotypes at the CNVs 
and flanking SNPs and indels. SHAPEIT2 requires each variant to be assigned a single 
genomic position. For each CNV longer than 10 kb we included the genotypes for that 
variant at the start-, mid- and endpoints of the CNV; for variants less than 10 kb we used the 
midpoint. We then ran SHAPEIT2 with parameters as for SNP/indel phasing to produce 
phased genotype calls, treating each CNV as a separate, biallelic variant. Next, to phase 
CNVs into the 1000 Genomes Project individuals, we extracted the Omni 2.5M sites with 
allele frequency > 1% from the 1000 Genomes Project phased haplotypes and removed the 
region of segmental duplication. We used MVNCALL to phase each non-singleton CNV 
into this scaffold, again placing each CNV greater than 10 kb in length at its start-, mid-, and 
end positions.
We assessed accuracy of phasing by considering patterns of LD between CNVs and variants 
in the left and right flanking regions (Figs. S9, S10). We noted high LD between some 
CNVs and variants to the left of the region, including for DEL1, DEL2, DUP1 and DUP4. 
LD estimated from phased haplotypes captured most of the correlation between genotypes 
across the region, as expected in an outbred population if haplotype phase is accurate. The 
small deviations observed may be due to the presence of a small number of switch errors, or 
potentially to population substructure.
Haplotype-based curation and re-phasing of CNVs—Some singleton CNVs have 
similar copy number profiles to more common CNVs in the HMM-based calls (22) and after 
phasing we observed that haplotypes carrying several of these clustered with the 
corresponding common variant (DEL9 with DEL1; DEL11, DEL12 and DEL14 with DEL2; 
DUP15 and DUP18 with DUP1). We reasoned that these are likely to represent the same 
variant, with differences in calling potentially due to noise in coverage profiles or variation 
in the other chromosome. We merged these singletons with the corresponding non-singleton 
CNV and repeated the procedure described above, using SHAPEIT2 and MVNCALL to re-
phase CNVs and flanking short variants then merging the two reference panels. We also 
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noted that haplotypes carrying DEL4 cluster with DUP1, which shares a similar breakpoint 
(Fig. 1B-C). A plausible explanation for this is that DUP1 arose by NAHR on a DEL4 
background (Fig. S24) (22).
For subsequent imputation steps we restricted the combined panel to the set of haplotypes 
from unrelated individuals (i.e. removing the children of family trios and duos). Three 
individuals in the 1000 Genomes data carry CNVs that are not singletons in the overall 
dataset but are private to that individual within the 1000 Genomes data (HG01986, carrying 
DEL4; HG02554, carrying DUP4, and HG02585, carrying DUP5). Of these, we noted in 
particular that HG02554 appears to have a switch error in the 1000 Genomes (explaining 
clustering of opposite haplotypes with other DUP4 haplotypes on either side of the region; 
Fig. S9). Because our approach phases variants in the 1000 Genomes separately and these 
are singletons in that dataset, we also excluded these three individuals from the panel used 
for imputation.
Cross-validation of CNV imputation in the reference panel—To evaluate how well 
CNVs are likely to be imputed in our GWAS dataset, we performed a cross-validation 
experiment using the African reference panel individuals as follows. For each individual, we 
removed the individual and his/her family members (if present) from the phased reference 
panel haplotypes to form a subsetted panel. We also extracted genotype calls for that 
individual at variants on the Illumina Omni 2.5M array from the reference panel genotypes, 
excluding variants within the glycophorin region. We used these genotypes and the subsetted 
panel to re-impute CNVs for that individual.
We evaluated CNV re-imputation by computing the correlation between HMM-based 
genotype calls and genotype dosages from the re-imputation (Fig. S11) and by direct 
comparison of HMM and re-imputed calls. We note that DEL4 carriers were imputed with 
some confidence as carrying DUP1, consistent with the shared haplotype for these variants 
and the higher frequency of DUP1. Given the functionally distinct nature of these variants, 
this affects interpretation of imputed DUP1 genotypes.
Among CNVs >10 kb in length, we noted little variation between the three imputation 
locations (leftmost breakpoint, midpoint, and rightmost breakpoint of the CNV), except for 
DUP4, where the right endpoint had slightly higher imputation performance (Fig. S11). For 
all analyses presented in this paper we refer to the midpoint imputation of each CNV.
Imputation of CNVs—We used the combined panel to impute CNVs into the three GWAS 
datasets. Imputation settings were as described above. To ensure imputation was based on 
flanking SNPs, we removed SNPs within the glycophorin region from the genotype data 
before imputation. We evaluated imputation performance in the GWAS data by comparing 
the overall expected allele frequency against the IMPUTE info metric and another metric of 
confidence in imputed CNV call probabilities, the proportion of expected frequency of CNV 
heterozygote or homozygote that is due to genotypes with at least 90% probability (Figs. 
3D, S12A-B). We also compared the expected frequency in control samples with the 
frequency in the geographically nearest reference panel population (Fig. S12C).
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Analysis of association at CNVs
Association with severe malaria—We tested for association with each CNV in each 
population using logistic regression including five principal components as covariates, and 
computed both fixed-effect and Bayesian meta-analyses as described above for SNPs and 
indels. To directly estimate the effect of heterozygote and homozygote genotypes, we 
modified SNPTEST to fit the logistic regression model with a separate parameter for 
heterozygote and homozygote genotypes in a missing data likelihood framework that 
integrates over imputation uncertainty. To assess evidence for association after accounting 
for DUP4, we used QCTOOL v2 (http://www.well.ox.ac.uk/~gav/qctool_v2/) to extract the 
additive and heterozygote imputed dosages of DUP4 for each individual, and repeated the 
association test and meta-analysis at SNPs, indels and CNVs conditioning on these dosages 
(Figs. 3B, S13).
Association with clinical subtypes—Severe malaria-affected children in our data are 
recorded as either having cerebral malaria (CM), severe malarial anaemia (SMA), or other 
nonspecific severe malaria phenotype (OTHER). To assess the association of DUP4 with 
these subphenotypes, we fit a multinomial logistic regression model with these outcome 
levels using population controls as a baseline (Table S7). A small number of individuals are 
annotated as both CM and SMA and were excluded from this analysis.
Association with gene content—To test for association with overall copy number of 
each glycophorin gene, we used the imputed genotype probabilities and the copy number 
profile of non-singleton CNVs (Fig. 1B) to compute the expected number of copies of each 
gene in each GWAS sample. Since overlap of some CNVs with genes is partial, we 
measured copy number separately at the transcription start and end sites. We also computed 
the expected number of hybrid genes as formed by DUP2, DUP4 and DUP8. We tested for 
association with each copy number measure by fitting a logistic regression model across the 
three populations, including the genic dosage and five principal components in each 
population. Overall genic copy number was significantly associated with severe malaria 
status (e.g. P=3x10-7 for dosage at transcription start sites), as was the expected number of 
hybrid genes. However, these effects were well explained by the effect of DUP4 (P > 0.14 
after conditioning on the expected dosage of DUP4). We note that several of these predictors 
are strongly correlated with DUP4 dosage; this analysis could not distinguish between an 
effect of DUP4 and that of copy number of GYPE, copy number of the GYPA transcription 
end site, or the total copy number of hybrid genes (P > 0.13 for either effect in a joint 
model).
We also specifically tested whether the number of deleted copies of GYPB, or the presence 
of one or two deleted copies, was associated with severe malaria status, but saw no evidence 
of association (P>0.48).
Population genetic analysis
Frequency differentiation—We used estimated minor allele frequencies (MAF) at both 
typed and imputed variants from (14) for the 2,490 population controls from the Gambia and 
1,498 population controls from Kenya to investigate the extent to which the observed 
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frequency difference of DUP4 is extreme relative to other variants genome-wide. For this 
comparison, we included all autosomal variants having IMPUTE info >0.75 and estimated 
frequency ≥0.5% in at least one of the populations (14,973,426 variants in total). We binned 
variants into 0.5% MAF bins and noted the frequency estimates for DUP4 (fKenya=0.0895 
and fGambia=0.0003) and, for comparison, the sickle cell anaemia-causing allele (rs334:T; 
MAF=0.0853 in Kenya and 0.0766 in the Gambia based on direct Sequenom typing of this 
SNP in these samples (68)).
To quantify the extent to which DUP4 is an outlier, we computed two empirical P-values 
based on the marginal distributions. Specifically, we computed PGambia|Kenya as the 
proportion of variants with MAF less than or equal to fGambia in the Gambia, among all 
variants with MAF within 1% of fKenya in Kenya (empirical PGambia|Kenya<1.2x10-6; 0 of 
831,956 variants in this bin). Similarly, we computed PKenya|Gambia as the proportion of 
variants with MAF equal to or greater than fKenya in Kenya, among all variants with MAF 
within 1% of fGambia in the Gambia (empirical PKenya|Gambia=1.7x10-3; 2,851 of 1,710,922 
variants in this bin).
We note that the computation of PGambia|Kenya is sensitive to the frequency of DUP4 in the 
Gambia, which may be underestimated due to poor imputation performance. To account for 
this we recomputed PGambia|Kenya assuming 1% frequency in the Gambia (adjusted empirical 
PGambia|Kenya=5x10-3) and refer to this value in the main text.
Haplotype homozygosity—To assess haplotype homozygosity, we first used SHAPEIT2 
to phase imputed CNV genotypes onto haplotypes defined by directly-typed SNPs in the 
region chr4:139.5-150.5Mb, excluding SNPs in the glycophorin region. We specified 400 
selected and 200 random copying states (--states 400, --states-random 200), an effective 
population size of 17,469 as recommended for African populations, and included reference 
panel haplotypes to inform phasing. EHH (27) was then computed around DUP4 using the 
rehh R package. We used a custom script to compute an unstandardized integrated haplotype 
score (uiHS) (26), using recombination rate estimates from the HapMap combined 
recombination map (52).
To generate a distribution of uiHS at SNPs with a similar frequency to DUP4, we computed 
uiHS at those genotyped SNPs (14) where the human ancestral allele could be inferred using 
the six primate EPO alignments (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/phase1/
analysis_results/supporting/ancestral_alignments/), and the derived allele frequency was in 
the 2% frequency bin centered around fKenya (0.0795-0.0995). We computed an empirical P-
value as the proportion of SNPs with uiHS less than or equal to that observed at DUP4 
(P=0.0119; 996 of the 83,419 variants in this bin). We note that the exclusion of the 
glycophorin region from the estimate at DUP4 is likely to be conservative, since in effect it 
adds a constant term equal to the recombination length of the removed interval 
(approximately 0.15 cM) to both the numerator and denominator of the statistic.
Resolution of the structure of DUP4
Discordant read pair analysis—We began by remapping reads from each of the nine 
heterozygous DUP4 carriers genome-wide using bwa mem, which has better performance 
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for longer reads (69). Because even longer reads should facilitate more confident mapping 
around the breakpoints, we also obtained DNA from Coriell for HG02554, the 1000 
Genomes sample carrying DUP4, and generated 300 bp PE sequence data on Illumina 
MiSeq at the High Throughput Genomics core at the Wellcome Trust Centre for Human 
Genetics at the University of Oxford. We mapped these reads to the same GRCh37 human 
reference (hs37d5.fa) with bwa mem, yielding 13x genomic coverage. For all re-mapped 
bam files, we marked duplicates with Picard MarkDuplicates and excluded duplicate reads 
from further analysis.
We then used samtools to pull out read pairs where both reads had a primary alignment to 
the glycophorin region with MQ≥1 and an absolute insert size ≥1 kb. For the 300 bp data, 
we allowed one of the reads in the pair to be mapped to the glycophorin region with MQ=0. 
Across samples, there were 434 such read pairs. We grouped read pairs where both ends 
were mapped within 1 kb of each other and identified those near the HMM-inferred 
breakpoints.
To view how uniquely the discordant read pairs matched each of the three possible 
homologous positions in the segmental duplication, we used the mapped position and the 
cigar string to place each read into the multiple sequence alignment and then identified 
positions in the read with a match or mismatch to each of the three aligned reference 
sequences using custom scripts in R (e.g., Fig. S16).
Molecular assays and Sanger sequencing—Briefly, a 4.1 kb fragment spanning the 
GYPB-A hybrid breakpoint (located between exons 4 and 5) was amplified by PCR using 
primers designed against GYPB and GYPA sequences (Fig. S17 and Table S10). In practice, 
it is difficult to design specific primers due to the high homology and the assay amplifies 
both GYPA and GYPB-A hybrid sequences. To separate these, we identified a restriction 
enzyme site (BlpI [5'…GC/TNAGC…3']) that cleaves the GYPA sequence but not that of 
the hybrid. PCR products were digested and then separated on an agarose gel. We excised 
the 4.1 kb band and obtained Sanger sequence of the region around the putative breakpoint 
(Figs. S18, S19). A full description of the design and protocols is given in (22).
Sequencing and copy number analysis of a serologically-typed Dantu+ 
individual—We obtained DNA from the International Blood Group Reference Laboratory 
in Bristol, UK from an archived reference sample that had been serologically typed as Dantu
+ (NE type). This sample was collected in 1992 and the individual was originally from 
Natal, South Africa. The DNA was sequenced with 150 bp PE reads on Illumina HiSeq 4000 
by the High Throughput Genomics core at the Wellcome Trust Centre for Human Genetics 
at the University of Oxford. Reads were mapped to the same GRCh37 human reference 
genome (hs37d5.fa) with bwa mem, yielding 18x coverage. To generate CNV calls, we ran 
our HMM method on this individual alone, without using the window-specific factors.
Simulations of DUP4 formation—To determine possible routes to formation of DUP4, 
we implemented a computer program in C++ to iteratively generate structural 
rearrangements via unequal crossing over, allowing breakpoints to occur at any of the six 
locations observed for DUP4 with no constraint based on homology. In brief, we encode the 
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reference haplotype as a string of seven segments delineated by the coverage breakpoints 
(i.e., as the string 0123456; Fig. 6A). We ran the program through three generations of 
events, where the first generation produced all possible events between two reference 
haplotypes and the second and third generations allowed unequal crossing over between any 
two haplotypes from previous generations. This brute force search allows us to place a lower 
limit of four on the number of events required to form DUP4. For additional details on the 
program and search, see (22).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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One sentence summary
Resolution of copy number changes in African populations reveals a complex structural 
variant that encodes hybrid genes and confers resistance to severe malaria.
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Fig. 1. Copy number variants in the glycophorin region.
(A) Mappability in the glycophorin region. The number of mappable sites and the maximum 
pairwise identity between homologous locations in the segmental duplication are shown in 
1600 bp windows. Pairwise identity is inferred from a multiple sequence alignment, with 
mean of 0.96 indicated with a red dashed line. The locations of protein-coding genes and the 
segmentally duplicated units are indicated below, with sequences of at least 100 bp that are 
unique to one or two out of the three segmentally duplicated units marked in black and gray, 
respectively. (B) Sequence coverage in 1600 bp windows and copy number for non-singleton 
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CNVs. Black dashes show the mean normalized sequence coverage across heterozygous 
individuals not carrying another CNV. Only windows input to the HMM are shown. The 
inferred CNVs are indicated with deletion in yellow, duplication in light blue, and 
triplication in dark blue. A horizontal gray line indicates the expected coverage without copy 
number variation and blue vertical lines mark the locations of the three genes. (C) Positions 
of breakpoints, colored as the variant names in (B) and shaded by whether the variant has a 
single pair of homologous breakpoints, a single pair of non-homologous breakpoints, or is a 
multi-segment CNV. The recombination rate from LD-based recombination maps (52, 53) 
and locations of DSB hotspots (24) are annotated below.
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Fig. 2. Frequency of CNVs in the sampled populations.
Populations are grouped on the basis of geographical proximity; abbreviations can be found 
in Tables S1 and S3.
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Fig. 3. Evidence of association.
(A) The evidence for association at SNPs, short indels, and CNVs across the glycophorin 
region. P-values are computed under an additive model of association using meta-analysis 
across the three African populations included in our study. Points are colored by LD with 
DUP4 in east African reference panel populations. Directly typed SNPs are denoted with 
black plusses, and CNVs with diamonds. Black triangles represent SNPs where the 
association signal was previously reported and replicated in further samples. CNV copy 
number profiles, as in Fig. 1B, and protein-coding genes are shown below. (B) Comparison 
of unconditional association test P-values (y axis, as in panel (A)), and after additionally 
conditioning on genotypes at DUP4 (x axis). (C) The evidence for association at DUP4. 
Colored circles and text show the estimated allele frequency of DUP4 in population controls 
and severe malaria cases. To the right is the odds ratio and 95% confidence interval for 
DUP4 heterozygotes (diamonds) and homozygotes (circles) relative to non-carriers. The 
bottom two rows represent effect sizes computed by fixed-effect meta-analysis. Sample sizes 
(number of controls/number of cases) are denoted to the left. (D) Comparison of IMPUTE 
info score and expected imputed allele frequency for the four annotated CNVs.
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Fig. 4. The effect of DUP4 on SNP array intensities.
(A) Normalized Illumina Omni 2.5M intensity values at selected SNP assays across the 
glycophorin region for reference panel individuals (top row; N=367 individuals from 
Burkina Faso, Cameroon, and Tanzania) and Kenyan GWAS individuals (second row, N = 
3,142). Blue and yellow points represent individuals heterozygous or homozygous for DUP4 
respectively, as determined by the HMM in reference panel individuals and by imputation in 
Kenya (genotypes with posterior probability at least 0.75). Arrows denote the mapping 
location of these SNPs. (B) The copy number profile of DUP4. (C) Position of the 
glycophorin genes and exons.
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Fig. 5. DUP4 frequency and haplotype homozygosity.
(A) The empirical joint allele-frequency spectrum for population controls in the Gambia and 
Kenya, in 0.5% frequency bins between 0 and 20%. The frequencies of DUP4 and rs334 are 
highlighted. Histograms show the frequency in the Gambia of SNPs in the DUP4 frequency 
bin in Kenya (8.5-9%, top) and the frequency in Kenya of SNPs in the DUP4 frequency bin 
in the Gambia (0-0.5%, right). (B) The estimated frequency of DUP4 in east African 
populations, shown with 95% confidence intervals and the number of haplotypes sampled. 
Estimates are from population controls in the GWAS or from the HMM genotype calls in the 
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reference panel (daggers). The dotted vertical line denotes the overall frequency of DUP4 in 
Kenyan controls. (C) Extended haplotype homozygosity (EHH) computed outward from the 
glycophorin region for DUP4 haplotypes and non-DUP4 haplotypes in Kenya, after 
excluding other variants within the glycophorin region. Below, the empirical distribution of 
unstandardized iHS for all typed SNPs within 1% frequency of DUP4 in Kenyan controls, 
with empirical P-value annotated. (D) The 272 haplotypes imputed to carry DUP4 and a 
random sample of 272 non-DUP4 haplotypes in Kenya. Haplotypes in each panel are 
clustered on 1 Mb extending in either direction from the glycophorin region, which is 
shaded in blue. The bar on the left depicts the population for each haplotype with colors as 
in panel (B). Recombination rate estimates (52, 53) are shown above and protein-coding 
genes below.
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Fig. 6. The structure of DUP4.
(A) Discordant read pairs mapped near DUP4 copy number changes. Colored arrows 
represent read pairs from DUP4 carriers, with paired reads shown on the same horizontal 
line and the direction of the arrows depicting the strand and position as mapped to the 
human reference sequence. The number of such read pairs and distinct carriers is given to 
the left. A schematic of the reference sequence is below with colors indicating the 
segmentally duplicated units. Brackets delineate segments with different copy number in 
DUP4, numbered and labeled with their length to the nearest kb. (B) The structure of DUP4, 
inferred by connecting sequence at breakpoints based on sequence homology and discordant 
read pairs. Arrows depict the concordant positions of the read pairs in (A) on this structure, 
and the order of reference segments is shown below. Inset: detail of the inferred GYPB-A 
hybrid genes, indicating the positions of discordant read pairs (arrows), PCR primers 
(vertical red lines) and the resulting product (horizontal red line). (C) Normalized coverage 
in 1600 bp windows (black) and HMM path (red) for a DUP4 carrier (top) and for an 
individual serotyped as Dantu+ (NE type; bottom), on the same x axis as (A). (D) Protein 
sequences of GYPA, GYPB, and the Dantu hybrid within the cell membrane depicting the 
extracellular, transmembrane, and intracellular domains as visualised with protter (54).
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